Neuronetics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Neuronetics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $15.58M | Mar 2, 2021 |
| FY2020 | Sep 30, 2020 | $12.45M | Mar 2, 2021 |
| FY2020 | Jun 30, 2020 | $9.74M | Mar 2, 2021 |
| FY2020 | Mar 31, 2020 | $11.48M | Mar 2, 2021 |
| FY2020 | Dec 31, 2019 | $17.36M | Mar 2, 2021 |
| FY2020 | Sep 30, 2019 | $16.00M | Mar 2, 2021 |
| FY2020 | Jun 30, 2019 | $16.57M | Mar 2, 2021 |
| FY2020 | Mar 31, 2019 | $12.73M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $15.64M | Mar 3, 2020 |
| FY2019 | Sep 30, 2018 | $13.74M | Mar 3, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.16M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $74.89M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $71.35M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $65.21M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $55.31M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $49.24M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $62.66M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $52.78M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $40.43M | Mar 3, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.31M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $54.16M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $51.71M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $49.72M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $43.66M | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $11.82M | Mar 2, 2021 |
| FY2020 | Sep 30, 2020 | $9.79M | Mar 2, 2021 |
| FY2020 | Jun 30, 2020 | $7.42M | Mar 2, 2021 |
| FY2020 | Mar 31, 2020 | $8.67M | Mar 2, 2021 |
| FY2020 | Dec 31, 2019 | $13.14M | Mar 2, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.00M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($43.71M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($30.19M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | ($37.16M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($31.19M) | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | ($3.66M) | Mar 2, 2021 |
| FY2020 | Sep 30, 2020 | ($3.42M) | Mar 2, 2021 |
| FY2020 | Jun 30, 2020 | ($7.77M) | Mar 2, 2021 |
| FY2020 | Mar 31, 2020 | ($12.61M) | Mar 2, 2021 |
| FY2020 | Dec 31, 2019 | ($7.55M) | Mar 2, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.44M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($34.56M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($30.55M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | ($35.11M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($27.56M) | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | ($2.66M) | Mar 2, 2021 |
| FY2020 | Sep 30, 2020 | ($2.42M) | Mar 2, 2021 |
| FY2020 | Jun 30, 2020 | ($6.86M) | Mar 2, 2021 |
| FY2020 | Mar 31, 2020 | ($10.37M) | Mar 2, 2021 |
| FY2020 | Dec 31, 2019 | ($6.94M) | Mar 2, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.58M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $12.77M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $9.52M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $9.34M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $7.92M | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $2.11M | Mar 2, 2021 |
| FY2020 | Sep 30, 2020 | $1.95M | Mar 2, 2021 |
| FY2020 | Jun 30, 2020 | $2.12M | Mar 2, 2021 |
| FY2020 | Mar 31, 2020 | $3.02M | Mar 2, 2021 |
| FY2020 | Dec 31, 2019 | $4.25M | Mar 2, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.37M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($31.00M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($32.04M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | ($30.74M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($27.98M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | ($28.39M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | ($30.48M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | ($20.59M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | ($11.14M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($8.54M) | Mar 5, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.55M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $140.90M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $115.83M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $116.88M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $141.22M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $78.66M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $100.17M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $117.02M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $38.94M | Mar 5, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.31M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $109.10M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $81.64M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $59.82M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $56.05M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $53.16M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $52.32M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $45.98M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $44.45M | Mar 5, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.38M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $27.71M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $34.19M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $57.06M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $85.18M | Mar 8, 2024 |
| FY2023 | Dec 31, 2020 | $25.49M | Mar 8, 2024 |
| FY2022 | Dec 31, 2019 | $47.85M | Mar 7, 2023 |
| FY2021 | Dec 31, 2018 | $71.04M | Mar 8, 2022 |
| FY2020 | Dec 31, 2017 | ($192.65M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2016 | ($177.12M) | Mar 3, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.62M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $18.63M | Mar 17, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($458.79M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($419.79M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($376.08M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($345.89M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($308.73M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($277.54M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($250.09M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | ($221.04M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($196.95M) | Mar 5, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.13M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $18.46M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $59.68M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $70.34M | Mar 27, 2025 |
| FY2022 | Dec 31, 2021 | $94.14M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $48.96M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $75.71M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $104.58M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $29.15M | Mar 5, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.81M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $55.15M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $59.28M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $35.95M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $35.34M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $34.62M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $31.15M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $30.40M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $29.56M | Mar 5, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 68.99M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 55.68M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 29.09M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 27.27M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 26.40M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 19.11M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 18.65M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | 17.74M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 231,000 | Mar 5, 2019 |